Read More Analyst Ratings News Price Target Raymond James Maintains Outperform on Walmart, Lowers Price Target to $165 By Benzinga Newsdesk February 22, 6:20 AM Raymond James analyst Bobby Griffin maintains Walmart (NYSE:WMT) with a Outperform and lowers the price target from $170 to $165. WMT
Read More Biotech FDA General Health Care Large Cap News Sanofi’s Rare Disease Drug Xenpozyme Scores FDA Approval By Vandana Singh September 1, 6:51 AM Soon after the European Commission’s (EC) approval, Sanofi SA (NASDAQ:SNY) scooped up the FDA’s OK for the first approved therapy to treat symptoms… SNY
Read More Dividends Earnings News If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,800 Today By Benzinga Insights February 22, 12:04 PM Lululemon Athletica (NASDAQ:LULU) has outperformed the market over the past 5 years by 23.46% on an annualized basis… LULU
Read More Analyst Ratings What To Know About Jefferies’s Downgrade of TCR2 Therapeutics By Benzinga Insights March 9, 1:02 PM Jefferies downgraded its rating of TCR2 Therapeutics (NASDAQ:TCRR) to Underperform with a price target of $3.00, changing its… TCRR